INTRODUCTION: Exocrine pancreatic cancers include common type pancreatic ductal adenocarcinoma and cystic neoplasms, which account for 85% and 10% of cases, respectively. The remaining 5% are rare histotypes, comprising adenosquamous carcinoma, acinar cell carcinoma, signet ring cell carcinoma, medullary carcinoma, pancreatoblastoma, hepatoid carcinoma, undifferentiated carcinoma and its variant with osteoclast-like giant cells, solid pseudopapillary carcinoma, and carcinosarcoma. Due to their low incidence, little knowledge is available on their clinical and molecular features as well as on treatment choices. The national initiative presented here aims at the molecular characterization of series of rare histotypes for which therapeutic and follow-up data are available. METHODS: A nationwide Italian Rare Pancreatic Cancer (IRaPaCa) task force whose first initiative is a multicentric retrospective study involving 21 Italian cancer centers to retrieve histologic material and clinical and treatment data of at least 100 patients with rare exocrine pancreatic cancers has been created. After histologic revision by a panel of expert pathologists, DNA and RNA from paraffin tissues will be investigated by next-generation sequencing using molecular pathway-oriented and immune-oriented mutational and expression profiling panels constructed availing of the information from the International Cancer Genome Consortium. Bioinformatic analysis of data will drive validation studies by immunohistochemistry and in situ hybridization, as well as nanostring assays. CONCLUSIONS: We expect to gather novel data on rare pancreatic cancer types that will be useful to inform the design of therapeutic choices.

The Italian Rare Pancreatic Exocrine Cancer Initiative / Brunetti, Oronzo; Luchini, Claudio; Argentiero, Antonella; Tommasi, Stefania; Mangia, Anita; Aprile, Giuseppe; Marchetti, Paolo; Vasile, Enrico; Casadei Gardini, Andrea; Scartozzi, Mario; Barni, Sandro; Delfanti, Sara; De Vita, Fernando; Di Costanzo, Francesco; Milella, Michele; Cella, Chiara Alessandra; Berardi, Rossana; Cataldo, Ivana; Santini, Daniele; Doglioni, Claudio; Maiello, Evaristo; Lawlor, Rita T; Mazzaferro, Vincenzo; Lonardi, Sara; Giuliante, Felice; Brandi, Giovanni; Scarpa, Aldo; Cascinu, Stefano; Silvestris, Nicola. - In: TUMORI. - ISSN 2038-2529. - (2019), pp. 1-10. [10.1177/0300891619839461]

The Italian Rare Pancreatic Exocrine Cancer Initiative

Casadei Gardini, Andrea;Scartozzi, Mario;Cascinu, Stefano;
2019

Abstract

INTRODUCTION: Exocrine pancreatic cancers include common type pancreatic ductal adenocarcinoma and cystic neoplasms, which account for 85% and 10% of cases, respectively. The remaining 5% are rare histotypes, comprising adenosquamous carcinoma, acinar cell carcinoma, signet ring cell carcinoma, medullary carcinoma, pancreatoblastoma, hepatoid carcinoma, undifferentiated carcinoma and its variant with osteoclast-like giant cells, solid pseudopapillary carcinoma, and carcinosarcoma. Due to their low incidence, little knowledge is available on their clinical and molecular features as well as on treatment choices. The national initiative presented here aims at the molecular characterization of series of rare histotypes for which therapeutic and follow-up data are available. METHODS: A nationwide Italian Rare Pancreatic Cancer (IRaPaCa) task force whose first initiative is a multicentric retrospective study involving 21 Italian cancer centers to retrieve histologic material and clinical and treatment data of at least 100 patients with rare exocrine pancreatic cancers has been created. After histologic revision by a panel of expert pathologists, DNA and RNA from paraffin tissues will be investigated by next-generation sequencing using molecular pathway-oriented and immune-oriented mutational and expression profiling panels constructed availing of the information from the International Cancer Genome Consortium. Bioinformatic analysis of data will drive validation studies by immunohistochemistry and in situ hybridization, as well as nanostring assays. CONCLUSIONS: We expect to gather novel data on rare pancreatic cancer types that will be useful to inform the design of therapeutic choices.
9-apr-2019
1
10
The Italian Rare Pancreatic Exocrine Cancer Initiative / Brunetti, Oronzo; Luchini, Claudio; Argentiero, Antonella; Tommasi, Stefania; Mangia, Anita; Aprile, Giuseppe; Marchetti, Paolo; Vasile, Enrico; Casadei Gardini, Andrea; Scartozzi, Mario; Barni, Sandro; Delfanti, Sara; De Vita, Fernando; Di Costanzo, Francesco; Milella, Michele; Cella, Chiara Alessandra; Berardi, Rossana; Cataldo, Ivana; Santini, Daniele; Doglioni, Claudio; Maiello, Evaristo; Lawlor, Rita T; Mazzaferro, Vincenzo; Lonardi, Sara; Giuliante, Felice; Brandi, Giovanni; Scarpa, Aldo; Cascinu, Stefano; Silvestris, Nicola. - In: TUMORI. - ISSN 2038-2529. - (2019), pp. 1-10. [10.1177/0300891619839461]
Brunetti, Oronzo; Luchini, Claudio; Argentiero, Antonella; Tommasi, Stefania; Mangia, Anita; Aprile, Giuseppe; Marchetti, Paolo; Vasile, Enrico; Casadei Gardini, Andrea; Scartozzi, Mario; Barni, Sandro; Delfanti, Sara; De Vita, Fernando; Di Costanzo, Francesco; Milella, Michele; Cella, Chiara Alessandra; Berardi, Rossana; Cataldo, Ivana; Santini, Daniele; Doglioni, Claudio; Maiello, Evaristo; Lawlor, Rita T; Mazzaferro, Vincenzo; Lonardi, Sara; Giuliante, Felice; Brandi, Giovanni; Scarpa, Aldo; Cascinu, Stefano; Silvestris, Nicola
File in questo prodotto:
File Dimensione Formato  
10.1177@0300891619839461.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 85.17 kB
Formato Adobe PDF
85.17 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1177514
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 6
social impact